Stockscreener 앱 받기
527.00
0.63%
-3.35
시간 외 거래:
527.00
전일 마감가:
$530.35
열려 있는:
$528.36
하루 거래량:
504.82K
Relative Volume:
1.15
시가총액:
$23.10B
수익:
$3.18B
순이익/손실:
$1.33B
주가수익비율:
18.89
EPS:
27.9001
순현금흐름:
$1.04B
1주 성능:
-1.09%
1개월 성능:
+9.67%
6개월 성능:
+26.21%
1년 성능:
+65.28%
1일 변동 폭
$524.30
$533.73
1주일 범위
$523.50
$543.37
52주 변동 폭
$266.98
$548.12
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, ZTS, HLN, TEVA
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Underweight |
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
Biotech Stocks Worth WatchingMarch 18th - MarketBeat
MannKind: Strategic Uncertainty Follows United Therapeutics' Pivot (Rating Downgrade) - Seeking Alpha
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock - MarketBeat
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells 9,500 Shares - TradingView
United Therapeutics Corporation $UTHR Holdings Lifted by L2 Asset Management LLC - MarketBeat
Assessing United Therapeutics (UTHR) Valuation After TETON-2 Tyvaso Data And New US$2b Buyback Program - simplywall.st
Rothblatt of United Therapeutics sells $5.1 million in UTHR stock - Investing.com
Insider Sell: Judy Olian Sells Shares of United Therapeutics Cor - GuruFocus
Judy Olian sells 400 UTHR shares across March transactions (UTHR) - Stock Titan
United Therapeutics CEO Martine A. Rothblatt Executes Stock Sales - TradingView
United Therapeutics (UTHR) director sells 200 shares under 10b5-1 plan - Stock Titan
United Therapeutics (UTHR) CEO pre-planned option exercise and 9,500-share sale - Stock Titan
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 8,984 Shares - MarketBeat
United Therapeutics (NASDAQ:UTHR) CEO Sells $276,054.84 in Stock - MarketBeat
Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It - MSN
Rothblatt, United Therapeutics CEO, sells $5.1m in UTHR stock - Investing.com
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
United Therapeutics stock surges 32% in 6 months: Here's why - MSN
United Therapeutics Stock Surges 32% in 6 Months: Here's Why - Yahoo Finance
Van ECK Associates Corp Purchases 29,297 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Korea Investment CORP Has $5.90 Million Holdings in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Shares Jump 32% Over Six Months: The Reasons Explained - Bitget
UBS raises United Therapeutics stock price target to $705 on catalysts - Investing.com Nigeria
Cantor Fitzgerald raises United Therapeutics stock price target to $625 - Investing.com Nigeria
Cantor Fitzgerald raises United Therapeutics stock price target to $625 By Investing.com - Investing.com India
Inhaled IPF drug from United Therapeutics slows lung scarring in trial - Stock Titan
United Therapeutics (UTHR) CEO trades shares under 10b5-1 stock plan - Stock Titan
United Therapeutics: Ralinepag Is The Ultimate Defense Against Yutrepia (Rating Upgrade) - Seeking Alpha
Capital Fund Management S.A. Purchases 20,410 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics Corp (UTHR) Shares Up 3.04% on Mar 10 - GuruFocus
United Therapeutics (NASDAQ:UTHR) Sets New 1-Year HighHere's What Happened - MarketBeat
United Therapeutics stock hits all-time high at 537.83 USD - Investing.com
United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains? - Yahoo Finance
Grantham Mayo Van Otterloo & Co. LLC Acquires 6,079 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Insider Sell: Judy Olian Sells 200 Shares of United Therapeutics Corp (UTHR) - GuruFocus
United Therapeutics Corp (UTHR) Shares Up 8.91% on Mar 9 - GuruFocus
United Therapeutics Launches $1.5 Billion Accelerated Share Repurchases With Citi Under $2 Billion Buyback - TradingView
United Therapeutics CEO Martine A. Rothblatt Sells 9,500 Shares - TradingView
United Therapeutics stock jumps 9% on $2B buyback program - Investing.com
United Therapeutics at Leerink Conference: Advancing Pulmonary Treatments - Investing.com
United Therapeutics stock buyback signals franchise confidence, TD Cowen says - Investing.com Nigeria
United Therapeutics (NASDAQ:UTHR) Shares Gap UpStill a Buy? - MarketBeat
United Therapeutics authorizes $2 billion buyback program - Investing.com
United Therapeutics sends $1.5B upfront for stock, $500M left - Stock Titan
First Trust Advisors LP Trims Stake in United Therapeutics Corporation $UTHR - MarketBeat
Rhenman & Partners Asset Management AB Buys Shares of 8,000 United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Ralinepag Data Reshapes Pulmonary Hypertension And Valuation Story - simplywall.st
United Therapeutics Shares Positive Study Results for its Bioengineered Liver - Medical Product Outsourcing
Ray Kurzweil Sells 4,910 Shares of United Therapeutics Corp - GuruFocus
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
유나이티드 테라퓨틱스 주식 (UTHR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 17 '26 |
Sale |
536.75 |
9,500 |
5,099,104 |
40,513 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 16 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 16 '26 |
Sale |
533.90 |
9,500 |
5,072,019 |
40,513 |
| MALCOLM JAN | Director |
Mar 17 '26 |
Sale |
533.51 |
45 |
24,008 |
125 |
1.75%
2.39%
자본화:
|
볼륨(24시간):